JFG
KYTX icon

Jefferies Financial Group’s Kyverna Therapeutics KYTX Stock Holding History

Jefferies Financial Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Sell
23,920
-8,081
-25% -$67.3K ﹤0.01% 1512
2025
Q4 		$301K Buy
32,001
+15,701
+96% +$117K ﹤0.01% 1495
2025
Q3 		$97.8K Buy
+16,300
New +$65.2K ﹤0.01% 1342

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Jefferies Financial Group's KYTX Position: Q1 2026 in Review

Jefferies Financial Group reduced its Kyverna Therapeutics (KYTX) stake by 25% in Q1 2026, selling an estimated $67.3K and leaving 23,920 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Jefferies Financial Group first reported a position in KYTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $301K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Jefferies Financial Group held 23,920 shares of Kyverna Therapeutics worth $206K as of Q1 2026.
  • Jefferies Financial Group sold 8,081 Kyverna Therapeutics shares in Q1 2026, an estimated $67.3K.
  • Kyverna Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1512 holding.
  • Jefferies Financial Group first reported a position in Kyverna Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jefferies Financial Group's Kyverna Therapeutics position peaked at $301K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.